13,566 Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Bought by SG Americas Securities LLC

SG Americas Securities LLC purchased a new stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 13,566 shares of the company’s stock, valued at approximately $178,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Ameritas Investment Partners Inc. lifted its position in Y-mAbs Therapeutics by 39.9% in the 1st quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock valued at $60,000 after purchasing an additional 1,056 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Y-mAbs Therapeutics during the second quarter worth $297,000. Caxton Associates LP bought a new stake in Y-mAbs Therapeutics in the first quarter worth $306,000. Price T Rowe Associates Inc. MD grew its holdings in Y-mAbs Therapeutics by 8.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company’s stock valued at $345,000 after purchasing an additional 1,657 shares during the last quarter. Finally, Boston Partners bought a new stake in Y-mAbs Therapeutics during the first quarter valued at about $556,000. Institutional investors own 70.85% of the company’s stock.

Insider Buying and Selling at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 30,000 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $12.97, for a total value of $389,100.00. Following the sale, the insider now owns 67,681 shares in the company, valued at approximately $877,822.57. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Y-mAbs Therapeutics news, COO Joris Wilms sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the transaction, the chief operating officer now directly owns 30,600 shares in the company, valued at $449,514. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Thomas Gad sold 30,000 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $12.97, for a total transaction of $389,100.00. Following the sale, the insider now directly owns 67,681 shares of the company’s stock, valued at approximately $877,822.57. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 100,000 shares of company stock valued at $1,338,100 in the last 90 days. Insiders own 21.50% of the company’s stock.

Wall Street Analyst Weigh In

YMAB has been the subject of several analyst reports. BMO Capital Markets cut their target price on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a research report on Tuesday, August 13th. Wedbush reaffirmed an “outperform” rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a research report on Tuesday, September 10th. Canaccord Genuity Group restated a “buy” rating and issued a $26.00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. Morgan Stanley lowered their target price on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a report on Tuesday, August 13th. Finally, Truist Financial started coverage on shares of Y-mAbs Therapeutics in a research note on Friday, June 28th. They issued a “buy” rating and a $21.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Y-mAbs Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $21.14.

Y-mAbs Therapeutics Stock Up 0.1 %

NASDAQ YMAB opened at $14.87 on Thursday. The company’s 50 day moving average is $13.82 and its 200-day moving average is $13.14. The firm has a market cap of $652.54 million, a P/E ratio of -30.35 and a beta of 0.70. Y-mAbs Therapeutics, Inc. has a 12-month low of $4.69 and a 12-month high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative return on equity of 24.88% and a negative net margin of 28.44%. The firm had revenue of $22.80 million during the quarter, compared to analysts’ expectations of $23.09 million. During the same quarter in the previous year, the company posted ($0.14) earnings per share. Equities analysts expect that Y-mAbs Therapeutics, Inc. will post -0.6 EPS for the current year.

Y-mAbs Therapeutics Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.